Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

PARP1 Suppresses the Transcription of PD-L1 by Poly(ADP-Ribosyl)ating STAT3
Ling Ding, Xi Chen, Xiaqing Xu, et al.
Cancer Immunology Research (2018) Vol. 7, Iss. 1, pp. 136-149
Open Access | Times Cited: 103

Showing 1-25 of 103 citing articles:

Inflammation-induced DNA damage, mutations and cancer
Jennifer E. Kay, Elina Thadhani, Leona D. Samson, et al.
DNA repair (2019) Vol. 83, pp. 102673-102673
Open Access | Times Cited: 336
Development of Immunotherapy Combination Strategies in Cancer
Timothy A. Yap, Eileen E. Parkes, Weiyi Peng, et al.
Cancer Discovery (2021) Vol. 11, Iss. 6, pp. 1368-1397
Open Access | Times Cited: 239
Multifaceted Role of PARP-1 in DNA Repair and Inflammation: Pathological and Therapeutic Implications in Cancer and Non-Cancer Diseases
Simonetta Pazzaglia, Claudio Pioli
Cells (2019) Vol. 9, Iss. 1, pp. 41-41
Open Access | Times Cited: 172
The DNA Damage Response and Inflammation in Cancer
Vanessa Klapp, Beatriz Álvarez-Abril, Giuseppe Leuzzi, et al.
Cancer Discovery (2023) Vol. 13, Iss. 7, pp. 1521-1545
Open Access | Times Cited: 57
STING agonism overcomes STAT3-mediated immunosuppression and adaptive resistance to PARP inhibition in ovarian cancer
Liya Ding, Qiwei Wang, Antons Martincuks, et al.
Journal for ImmunoTherapy of Cancer (2023) Vol. 11, Iss. 1, pp. e005627-e005627
Open Access | Times Cited: 52
The generation of PD-L1 and PD-L2 in cancer cells: From nuclear chromatin reorganization to extracellular presentation
Zhiwei Fan, Changyue Wu, Miaomiao Chen, et al.
Acta Pharmaceutica Sinica B (2021) Vol. 12, Iss. 3, pp. 1041-1053
Open Access | Times Cited: 65
Interferon regulatory factor 1(IRF-1) activates anti-tumor immunity via CXCL10/CXCR3 axis in hepatocellular carcinoma (HCC)
Yihe Yan, Leting Zheng, Qiang Du, et al.
Cancer Letters (2021) Vol. 506, pp. 95-106
Open Access | Times Cited: 62
Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures
Xinke Zhang, Ying-Ying Wang, Abdulrahim Gari, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 58
PARP1: Liaison of Chromatin Remodeling and Transcription
Wen Zong, Yamin Gong, Wenli Sun, et al.
Cancers (2022) Vol. 14, Iss. 17, pp. 4162-4162
Open Access | Times Cited: 48
Canagliflozin primes antitumor immunity by triggering PD-L1 degradation in endocytic recycling
Ling Ding, Xi Chen, Wenxin Zhang, et al.
Journal of Clinical Investigation (2023) Vol. 133, Iss. 1
Open Access | Times Cited: 40
Mechanism of PARP inhibitor resistance and potential overcoming strategies
Xiaoyu Fu, Ping Li, Qi Zhou, et al.
Genes & Diseases (2023) Vol. 11, Iss. 1, pp. 306-320
Open Access | Times Cited: 29
Disulfiram combined with copper induces immunosuppression via PD-L1 stabilization in hepatocellular carcinoma.
Binghai Zhou, Lei Guo, Bo Zhang, et al.
PubMed (2019) Vol. 9, Iss. 11, pp. 2442-2455
Closed Access | Times Cited: 66
CD44 in Ovarian Cancer Progression and Therapy Resistance—A Critical Role for STAT3
Antons Martincuks, Pei-Chuan Li, Qianqian Zhao, et al.
Frontiers in Oncology (2020) Vol. 10
Open Access | Times Cited: 57
The pathogenesis and therapeutic strategies of heat stroke-induced liver injury
Fuquan Wang, Yan Zhang, Jianhua Li, et al.
Critical Care (2022) Vol. 26, Iss. 1
Open Access | Times Cited: 36
HBV DNA polymerase upregulates the transcription of PD-L1 and suppresses T cell activity in hepatocellular carcinoma
Yan Jia, Jianing Zhao, Chunqing Wang, et al.
Journal of Translational Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 7
Hepatoma cell-intrinsic TLR9 activation induces immune escape through PD-L1 upregulation in hepatocellular carcinoma
Binghai Zhou, Jiuliang Yan, Lei Guo, et al.
Theranostics (2020) Vol. 10, Iss. 14, pp. 6530-6543
Open Access | Times Cited: 46
Integrating Immunotherapy and Targeted Therapy in Cancer Treatment: Mechanistic Insights and Clinical Implications
Johann S. Bergholz, Qiwei Wang, Sheheryar Kabraji, et al.
Clinical Cancer Research (2020) Vol. 26, Iss. 21, pp. 5557-5566
Open Access | Times Cited: 43
ANXA1 Promotes Tumor Immune Evasion by Binding PARP1 and Upregulating Stat3-Induced Expression of PD-L1 in Multiple Cancers
Xiao Ding, Ting Zeng, Zhu Wei, et al.
Cancer Immunology Research (2023) Vol. 11, Iss. 10, pp. 1367-1383
Closed Access | Times Cited: 16
Immune checkpoint inhibitors in breast cancer: development, mechanisms of resistance and potential management strategies
Rachel SJ Wong, Rebecca JM Ong, Joline SJ Lim
Cancer Drug Resistance (2023) Vol. 6, Iss. 4, pp. 768-87
Open Access | Times Cited: 16
Anoikis resistance and immune escape mediated by Epstein-Barr virus-encoded latent membrane protein 1-induced stabilization of PGC-1α promotes invasion and metastasis of nasopharyngeal carcinoma
Chaoliang Liao, Min Li, Xue Chen, et al.
Journal of Experimental & Clinical Cancer Research (2023) Vol. 42, Iss. 1
Open Access | Times Cited: 14
The current status and future of PD-L1 in liver cancer
Liyuan Hao, Shenghao Li, Jiali Deng, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 14
Targeting PARG induces tumor cell growth inhibition and antitumor immune response by reducing phosphorylated STAT3 in ovarian cancer
Antons Martincuks, Chunyan Zhang, Theresa Austria, et al.
Journal for ImmunoTherapy of Cancer (2024) Vol. 12, Iss. 4, pp. e007716-e007716
Open Access | Times Cited: 5
Dihydropyridine Calcium Channel Blockers Suppress the Transcription of PD-L1 by Inhibiting the Activation of STAT1
Xiaohui Pan, Run Li, Hongjie Guo, et al.
Frontiers in Pharmacology (2021) Vol. 11
Open Access | Times Cited: 29
lncRNA MIAT targets miR‐411‐5p/STAT3/PD‐L1 axis mediating hepatocellular carcinoma immune response
Xiaoxia Zhang, Banglun Pan, Jiacheng Qiu, et al.
International Journal of Experimental Pathology (2022) Vol. 103, Iss. 3, pp. 102-111
Open Access | Times Cited: 22
PARP Inhibitors in Biliary Tract Cancer: A New Kid on the Block?
Angela Dalia Ricci, Alessandro Rizzo, Chiara Bonucci, et al.
Medicines (2020) Vol. 7, Iss. 9, pp. 54-54
Open Access | Times Cited: 28
Page 1 - Next Page

Scroll to top